Embrex Inc. announced Friday that it has filed a registrationstatement with the Securities and Exchange Commission (SEC)for a secondary public offering of 1.8 million newly issuedshares of common stock.

The managing underwriters of the offering will be JosephthalLyon & Ross Inc. and Foley Mufson Howe & Co.

Certain selling shareholders may offer additional shares as partof the underwriter overallotment options, Embrex said.

Embrex of Research Triangle Park, N.C., has developed andcommercialized an automated system for inoculating broilerchickens in ovo. The Inovoject system eliminates the need formanual post-hatch vaccination of chicks against commonafflictions such as Marek's disease, which if left untreatedcauses nervous system tumors that make the broilersunmarketable.

Embrex (NASDAQ:EMBX) has agreements to supply its Inovojectsystem to several large poultry producers. In early May, itamended an existing agreement with Tyson Foods, the leadingproducer of broiler chickens worldwide, so that Tyson willinstall Inovoject systems in 23 of its largest hatcheries.

Embrex's stock closed Friday at $8.38 a share, off 38 cents.

(c) 1997 American Health Consultants. All rights reserved.